GlobeNewswire PharmaOriginal article
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Phase 3positiveamlitelimabPositive
AI Analysis
Summary
Sanofi presented new Phase 3 study results for amlitelimab in atopic dermatitis at the American Academy of Dermatology conference in a late-breaking research session.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 study results presented in late-breaking research session at AAD conference
Importance:7/10
Sentiment:
0.70
Phase 3atopic dermatitisdermatologyconference presentationlate-breaking
Related Companies
Read the original article
Published by GlobeNewswire Pharma on March 28, 2026 3:00 PM